THE EFFECT AND SAFETY OF MONTELUKAST IN TREATMENT OF ASTHMATIC
CHILDREN
Cao Ling, Chen Yuzhi
Capital Institute of Pediatrics, Beijing, China
Objective: To observe the effect and safety of
Montelukast in treating children’s asthma.
Method: 10 mild to moderate asthmatic
children age frome 6-14 years, inhaled steroid not more than 400ug/day were
enrolled in every center. Montelukast was taken 5mg once daily, 8 weeks.
The symptom and sign score, side effect, and lungfountion index FEV1 and
PEFR were observed.
Result: 79 children completed this study.
Their symptom and sign score was reduced significantly. Inhaled β2 agonist as rescue medicine reduced
from 1.53 times/week to 0.11times/week. FEV1(1.358 vs 1.693L) and
PEFR(3.066 vs 3.964L/S) improved significantly. In order to delete the
influent of bronchodilator, FEV1 was tested after inhaled ventolin in 40
children before and after treatment. The result show FEV1(1.657 vs 1.841)
still improved significantly. All of the side effect were mild including 3 case
of headache, 2 of vomit, 1 of sick, 1of stomache and 1 of rash, using the
medicine continuously, all of side effect disappeared.
Conclusion: oral Montalukast 5mg once daily 8 weeks
can improve asthmatic symptom, reduce inhaledβ2 agonist as rescue medicine, improve
lungfunction and no severe side effect in 6-14 years children.